Roivant Sciences Ltd (ROIV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has a cash flow conversion efficiency ratio of -0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-196.48 Million) by net assets ($4.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Roivant Sciences Ltd (ROIV) balance sheet quality index to measure how much of total assets are equity-financed.
Roivant Sciences Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Roivant Sciences Ltd to evaluate the quality of earnings relative to operating cash generation.
Roivant Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roivant Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Okta Inc
NASDAQ:OKTA
|
0.040x |
|
China Merchants Securities Co Ltd
SHG:600999
|
-0.097x |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
0.067x |
|
Expeditors International of Washington, Inc.
NYSE:EXPD
|
0.135x |
|
Estee Lauder Companies Inc
NYSE:EL
|
0.103x |
|
Cognizant Technology Solutions Corp Class A
NASDAQ:CTSH
|
0.018x |
|
Jiangsu Hengli Hydraulic Co Ltd
SHG:601100
|
0.021x |
|
US Foods Holding Corp
NYSE:USFD
|
0.068x |
Annual Cash Flow Conversion Efficiency for Roivant Sciences Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Roivant Sciences Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ROIV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.19 Billion | $-839.45 Million | -0.162x | -36.37% |
| 2024-03-31 | $6.45 Billion | $-765.27 Million | -0.119x | +77.38% |
| 2023-03-31 | $1.61 Billion | $-843.39 Million | -0.525x | -59.58% |
| 2022-03-31 | $2.06 Billion | $-677.73 Million | -0.329x | -28.73% |
| 2021-03-31 | $2.16 Billion | $-552.14 Million | -0.255x | +29.31% |
| 2020-03-31 | $2.11 Billion | $-761.83 Million | -0.361x | +66.94% |
| 2019-03-31 | $937.30 Million | $-1.02 Billion | -1.093x | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more